Abstract: FR-PO0868
Health Outcome Disparities and Determinants of Progression in a Multiethnic Cohort of Patients with IgAN
Session Information
- Glomerular Outcomes: From Proteinuria to Prognosis
November 07, 2025 | Location: Exhibit Hall, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Glomerular Diseases
- 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics
Authors
- Vasquez-Rios, George, GN Center, Renal Medicine Associates, Albuquerque, New Mexico, United States
- Rajasekaran, Arun, GN Center, Renal Medicine Associates, Albuquerque, New Mexico, United States
- Posso Paz, Mariam B, The University of New Mexico, Albuquerque, New Mexico, United States
- Natarajan, Hariharasudan, Icahn School of Medicine at Mount Sinai Department of Medicine, New York, New York, United States
- Kumar, Jayant, GN Center, Renal Medicine Associates, Albuquerque, New Mexico, United States
- Madan, Arvind, GN Center, Central Florida Kidney Specialists, Orlando, Florida, United States
- Campbell, Kirk N., University of Pennsylvania, Philadelphia, Pennsylvania, United States
- Coca, Steven G., Icahn School of Medicine at Mount Sinai Department of Medicine, New York, New York, United States
- Sanchez Russo, Luis F., GN Center, Central Florida Kidney Specialists, Orlando, Florida, United States
Group or Team Name
- BRIDGE-GN Research Consortium.
Background
IgA nephropathy (IgAN) is the most common primary glomerulonephritis, with outcomes varying by ethnicity. Latino/Hispanic patients are underrepresented despite high CKD risk. This study investigates ethnic disparities and clinical predictors of progression in a U.S. IgAN cohort.
Methods
A retrospective cohort study (2015–2025) included adults with biopsy-confirmed primary IgAN from a GN registry. The primary outcome was a composite of ≥40% eGFR decline, eGFR <15 mL/min/1.73m2, progression to ESKD or kidney transplant, or death. Longitudinal eGFR and UPCR trajectories were assessed using linear mixed-effects models with random intercepts to account for repeated measures. Fixed effects included visit timepoint, ethnicity, and baseline values. Least Squares Means (LSMeans) were calculated by ethnicity and evaluated using fixed effect estimates. Baseline characteristics of disease progressors vs. non-progressors were compared using exact logistic regression.
Results
Among 79 patients, 68% were ethnic minorities (48% Hispanic/Latino; 20% Black/Asian/Other). Median age was 47; 51% were male. Baseline eGFR and UPCR were 55 mL/min/1.73m2 and 1.6 g/g, respectively. Adjusted LSMean eGFR was consistently higher in Caucasian patients, though decline rates were similar (p>0.05). LSMean UPCR was persistently higher in minorities, but not statistically significant (p=0.191). Progressors had lower baseline eGFR (35.5 vs. 62.1, p=0.009) and higher UACR (3.43 vs. 1.14, p=0.044). In exact logistic regression, lower eGFR (OR 0.93, CI 0.87–0.99; p=0.031) and higher UPCR (OR 1.45, CI 1.01–3.12; p=0.048) predicted progression. Ethnicity was not a significant predictor.
Conclusion
In this diverse IgAN cohort, ethnic minority patients had lower eGFR and higher proteinuria, though differences were not statistically significant. Lower baseline eGFR and higher proteinuria predicted progression, regardless of ethnicity. Larger studies are needed to clarify ethnic impact.
Table 1. Exact Logistic Regression Analysis for Predictors of IgAN Progression
| Variable | aOR | 95%CI | p-value |
| Age (years) | 0.95 | 0.88-1.03 | 0.095 |
| eGFR (mL/min) | 0.93 | 0.87-0.99 | 0.031 |
| UPCR (g/g) | 1.45 | 1.01-3.12 | 0.048 |